Cheelcare secures Medicare reimbursement for power assist device
By HME News Staff
Updated 9:27 AM CST, Tue January 27, 2026
MARKHAM, Ontario – Cheelcare has received Pricing, Data Analysis and Coding (PDAC) verification for its Companion power assist device, confirming reimbursement eligibility for Medicare and Medicaid under HCPCS code E0986. Historically, adoption of Companion has been primarily concentrated within Veterans Affairs (VA), vocational rehab and workers compensation programs. Medicare and Medicaid reimbursement represents a significantly larger addressable market, and the company expects this approval to accelerate sales activity across its existing U.S. dealer footprint. "PDAC approval of a product is a critical step that most DME dealers require," said Allan Boyd, Cheelcare's vice president of growth. "This approval confirms that dealers may bill Medicare for Companion under HCPCS code E0986, which is expected to reduce financial barriers to providing medically necessary equipment for users who would otherwise be required to pay out of pocket. This makes our technology more accessible to end-users who need it and gives therapists the ability to prescribe it without funding-related constraints." Cheelcare currently is represented by a growing network of more than 300 authorized dealers throughout the United States. The company also noted recent commercial momentum for Companion, with record assisted-device sales achieved in November and December 2025, reflecting growing demand within the U.S. market ahead of broader Medicare and Medicaid reimbursement availability.
Comments